Sirona Biochem Corp. announced the termination of the Rodan + Fields agreement for supply and use of TFC-1067 in commercial formulations. Allergan Aesthetics, will now be the sole licensee of the technology as per the agreement signed June 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.06 CAD | -14.29% | -14.29% | -50.00% |
Apr. 08 | Sirona Biochem Provides Update on Anti-Aging Product | MT |
Apr. 04 | Sirona Biochem Corp. announced that it has received CAD 0.1325 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-50.00% | 13.14M | |
+26.42% | 44.96B | |
-0.83% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.39% | 26.08B | |
-21.21% | 19.03B | |
+5.87% | 12.75B | |
+28.46% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- SBM Stock
- News Sirona Biochem Corp.
- Sirona Biochem Corp. Announces the Termination of Supply Agreement with Rodan+Fields